Workflow
德恩精工(300780) - 2025 Q4 - 年度业绩预告
2026-01-30 10:54
证券代码:300780 证券简称:德恩精工 公告编号:2026-003 四川德恩精工科技股份有限公司 | 项 目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | | -6,000 | ~ | -4,000 | -13,075.42 | | | 比上年同期增长 | 54.11% | ~ | 69.41% | | | 扣除非经常性损益后的净利润 | | -7,500 | ~ | -5,500 | -14,791.5 | | | 比上年同期增长 | 49.30% | ~ | 62.82% | | 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况:预计净利润为负值 (1)以区间数进行业绩预告的 单位:万元 二、与会计师事务所沟通情况 本次业绩预告的相关数据系公司财务部门初步测算结果,未经会计师事务所审计。公 司已就本次业绩预告有关事项与年审会计师事务所进行预沟通,公司与会计师事务所在业 绩预告方面不存在重大分歧。 2025 年度业绩预告 ...
路桥信息(920748) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示:本公告所载 2025 年年度主要财务数据为初步核算数据,未经会 计师事务所审计,具体数据以公司 2025 年年度报告中披露的数据为准,提请投 资者注意投资风险。 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 证券代码:920748 证券简称:路桥信息 公告编号:2026-006 厦门路桥信息股份有限公司 2025 年年度业绩预告公告 二、本期业绩重大变化的主要原因 报告期内,公司预计实现归母净利润-7,000 万元到-6,000 万元,主要是因 为:1、受 2025 年交通基础设施建设投资放缓影响,部分项目落地及交付周期延 后,使得全年收入规模同比下降约 50%;2、受 2025 年主要客户预算收紧等影响, 且软件等高毛利率业务占比有所降低,使得综合毛利率下降;3、受宏观经济等 影响,项目回款不及预期,应收账款账龄增加,相应的减值准备计提增加。 截至公告披露日,公 ...
美芯晟(688458) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
证券代码:688458 证券简称: 美芯晟 公告编号:2026-009 美芯晟科技(北京)股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 (三)本次所预计的业绩未经注册会计师审计。 二、上年同期业绩情况和财务状况 (一)2024 年度公司实现营业收入 40,416.79 万元,归属于母公司所有者 的净利润-6,656.71 万元,归属于母公司所有者的扣除非经常性损益的净利润 -9,308.20 万元。 (二)2024 年度归属于公司普通股股东的基本每股收益:-0.61 元。 三、本期业绩变化的主要原因 2025 年,公司坚持"手机+汽车+机器人"长期发展战略,高研发投入逐步 转化为核心技术领先优势,多款新产品已陆续实现量产出货;同时,成熟产品系 列依托设计优化、工艺迭代、供应链降本等方式进一步提升产品市场竞争力。以 上因素推动公司毛利率提升约 10 个百分点, ...
中孚信息(300659) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
Financial Performance Forecast - The company expects a net profit in 2025 to be in the range of -11,000 to -9,000 thousand CNY, representing a year-on-year growth of 12.11% to 28.09%[4] - The expected operating revenue for the reporting period is between 71,000 and 78,000 thousand CNY, reflecting a year-on-year decline of 0.67% to 9.58%[6] - The impact of non-recurring gains and losses on net profit for 2025 is estimated to be approximately 30,000 thousand CNY, mainly from government subsidies[7] Business Strategy and Operations - The company has been optimizing its business structure and maintaining a steady operational quality, leading to a significant increase in gross profit margin[6] - The company is focusing on deepening its market presence in the government and defense sectors, which is expected to support sustainable growth[7] - The company has launched several new products, including the Tianji Data Analysis Platform and AI Application and Service Platform, enhancing its core competitiveness[7] - The company is implementing cost reduction and efficiency improvement measures, resulting in a gradual improvement in its overall profit structure[7] Communication and Transparency - The company has communicated its performance forecast with its auditing firm, confirming no significant discrepancies[5] - The company emphasizes the importance of cautious decision-making for investors, as the performance forecast data is preliminary and unaudited[8] - The company will provide detailed data in its 2025 annual report[8]
皇台酒业(000995) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between 10 million and 15 million CNY, a decrease of 45.85% to 63.90% compared to 27.7 million CNY in the previous year[3] - The estimated net profit after deducting non-recurring losses is expected to be between 9.5 million and 14 million CNY, reflecting a decline of 10.49% to 31.91% from 10.61 million CNY in the previous year[3] - The basic earnings per share is projected to be between 0.06 CNY and 0.08 CNY, down from 0.16 CNY in the previous year[3] Reasons for Decline - The decline in net profit is attributed to the conclusion of a lawsuit in 2024, which had previously increased the net profit due to the reversal of estimated liabilities[5] Financial Reporting - The financial data presented is based on preliminary calculations by the company's finance department and has not yet been audited by the annual accounting firm[4] - The company advises investors to make cautious decisions and be aware of investment risks related to the preliminary nature of the earnings forecast[7]
泰达股份(000652) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
一、本期业绩预计情况 (一)业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日 (二)业绩预告情况:预计净利润为负值 1. 以区间数进行业绩预告的 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 亏损:25,000 | 万元~ 32,000 | 万元 盈利:11,410.98 | 万元 | | 扣除非经常性损益后的净利润 | 亏损:7,182.37 | 万元~14,182.37 | 万元 盈利:2,719.49 | 万元 | | 基本每股收益 | 亏损:0.1694 | 元/股~0.2169 | 元/股 盈利:0.0773 | 元/股 | 证券代码:000652 证券简称:泰达股份 公告编号:2026-8 天津泰达资源循环集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没 有虚假记载、误导性陈述或重大遗漏。 (一)报告期内,公司补缴税款及滞纳金共计 1.32 亿元,影响当期损益; (二)报告期内,由于参股公司天津滨海南港石油仓储 ...
华软科技(002453) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
证券代码:002453 证券简称:华软科技 公告编号:2026-003 金陵华软科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整,没有虚假记载、误导性陈述或者重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日 | 项 | 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东 | | 亏损:26,000-35,000 | 万元 | 亏损:28,761.90 万元 | | 的净利润 | | | | | | 扣除非经常性损益后 | | 亏损:26,100-35,100 | 万元 | 亏损:27,474.74 万元 | | 的净利润 | | | | | | 基本每股收益 | | 亏损:0.3201-0.4308 | 元/股 | 亏损:0.35 | 2、业绩预告情况:预计净利润为负值 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计。公司就本次业绩预告与年 度审计会计师事务所进行了预沟通,双方不存在重大分歧。 三、业绩 ...
金融街(000402) - 2025 Q4 - 年度业绩预告
2026-01-30 10:50
Financial Performance - The company expects a net profit attributable to shareholders to be a loss of between 450 million and 650 million yuan, compared to a loss of 1,108.372 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 430 million to 630 million yuan, compared to a loss of 997.901 million yuan in the previous year[3]. - The basic earnings per share is expected to be a loss of between 1.51 yuan and 2.17 yuan, compared to a loss of 3.71 yuan per share in the previous year[3]. Real Estate Development Losses - The company anticipates a loss of approximately 2.5 to 3 billion yuan from real estate development due to market pricing strategies and project settlement losses[6]. - An additional loss of about 1.5 to 3 billion yuan is expected from impairment provisions on certain inventory projects[6]. Cash Flow and Liabilities - The company aims to achieve a net cash flow from operating activities of approximately 2 billion yuan, maintaining positive cash flow for seven consecutive years[7]. - By the end of 2025, the company's cash balance is expected to be around 16.6 billion yuan, covering all interest-bearing liabilities due within one year for six consecutive years[7]. - The company plans to reduce interest-bearing liabilities by approximately 5 billion yuan by the end of 2026, following the repayment of financial products issued in December 2025[7]. Operational Focus - The company will focus on enhancing operational efficiency and cost control while promoting sales and project cash collection in its real estate development business[9]. - The company is committed to improving service levels and customer experience in its asset management business while expanding and upgrading urban renewal and cultural tourism projects[9].
凯龙高科(300912) - 2025 Q4 - 年度业绩预告
2026-01-30 10:46
一、本期业绩预计情况 证券代码:300912 证券简称:凯龙高科 公告编号:2026-004 凯龙高科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 三、业绩变动原因说明 1、公司2025年度业绩预计出现亏损,主要原因如下: 2025年度,受新能源汽车渗透率加快、行业竞争加剧、公司营业收入增长不 及预期、全产业链布局导致固定费用支出仍较高、同时冲回已确认的递延所得税 资产等因素的影响,归属于上市公司股东的净利润预计出现亏损。 2、2025年度与去年同期相比,实现减亏,主要原因如下: 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况: 预计净利润为负值 (1)以区间数进行业绩预告的 单位:万元 | 项 | 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | | -12,500 | ~ | -8,800 | -27,650.85 | | 扣除非经常性损益 后的净利润 ...
康芝药业(300086) - 2025 Q4 - 年度业绩预告
2026-01-30 10:46
Financial Performance Forecast - The estimated net profit for 2025 is projected to be a loss between CNY 168 million and CNY 238 million, compared to a loss of CNY 216.21 million in the same period last year [3]. - The estimated loss after deducting non-recurring gains and losses is projected to be between CNY 153 million and CNY 216 million, compared to a loss of CNY 213.10 million in the same period last year [3]. - The estimated impact of non-recurring gains and losses on net profit is approximately -CNY 18 million, primarily from government subsidies and changes in fair value of investment properties [5]. Market Competition and Costs - The main reason for the expected loss is increased competition in the pharmaceutical market, leading to higher sales and marketing expenses while total operating costs exceed total operating revenue [5]. Communication and Assessment - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant discrepancies in financial data [4]. - The performance forecast is based on preliminary calculations by the finance department and is subject to final assessments by evaluation and auditing institutions [7]. Investment Risks - Investors are advised to make cautious decisions and be aware of investment risks due to potential discrepancies in asset impairment and other results [7].